Opinion: PARP inhibitors in cancer—what do we still need to know?-Reference-Cited by-同舟云学术

Opinion: PARP inhibitors in cancer—what do we still need to know?

Published:2022-07 Issue:7 Volume:12 Page:
ISSN:2046-2441
Container-title:Open Biology
language:en
Short-container-title:Open Biol.

Author:

Wicks Andrew J.¹²^ORCID,Krastev Dragomir B.¹²,Pettitt Stephen J.¹²,Tutt Andrew N. J.²,Lord Christopher J.¹²

Affiliation:

1. The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK

2. Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK

Abstract

PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We discuss the need to refine the current repertoire of clinical-grade companion biomarkers to be used with PARPi, so that patient stratification can be improved, the early emergence of drug resistance can be detected and dose-limiting toxicity can be predicted. We also highlight current thoughts about how PARPi resistance might be treated.

Publisher

The Royal Society

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,General Neuroscience

Link

https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.220118

Reference116 articles.

1. Poly(ADP-ribose) and ADP-ribosylation of proteins;Hilz H;Rev. Physiol. Biochem. Pharmacol.,1976

2. ADP-ribosylation of nuclear proteins

3. The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication

4. High speed of fork progression induces DNA replication stress and genomic instability

5. Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas;Journal of Virology;2024-07-23

2. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells;Cell Reports;2024-05

3. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution;International Journal of Molecular Sciences;2024-04-07

4. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer;Annals of Oncology;2024-04

5. FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells;Nature Communications;2024-03-23